Canada· CA-DIN-02455420
INVOKAMET
A metformin and canagliflozin product containing canagliflozin + metformin hydrochloride, registered in Canada by JANSSEN INC. The same ATC class is registered in 11 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Metformin and canagliflozin is registered in 11 of 19 countries.
Countries holding a registration under ATC A10BD16 (metformin and canagliflozin), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Metformin and canagliflozin · ATC A10BD16
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- CANAGLIFLOZIN + METFORMIN HYDROCHLORIDE
- Manufacturer
- JANSSEN INC
- Country
- Canada (CA)
- ATC code
- A10BD16
- ATC class
- Metformin and canagliflozin
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for metformin and canagliflozin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and canagliflozin · interactions on record
2 records
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and canagliflozin in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesINVOKAMETJanssen Pharmaceuticals, Inc.
- CzechiaVOKANAMETJanssen-Cilag International N.V., Beerse
- SwitzerlandVokanamet 150 mg / 1000 mg, FilmtablettenJanssen-Cilag AG
- IcelandVokanametJanssen-Cilag International NV*
- NetherlandsVokanamet 150 mg/1.000 mg filmomhulde tablettenJanssen-Cilag International NV
- SwedenVokanamet 150 mg/1000 mg Filmdragerad tablettJanssen-Cilag International NV
- PolandVokanametJanssen-Cilag International N.V.
- SpainVOKANAMET 150 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vokanamet
- Liechtenstein · Vokanamet
- Norway · Vokanamet
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0fa15e7b-2347-45c1-b37b-55fd0611d097 GET /v1/drugs/0fa15e7b-2347-45c1-b37b-55fd0611d097?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02455420",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A10BD16",
"schedule": [
"Prescription"
],
"drug_code": "94223",
"strengths": [
"50 MG",
"1000 MG"
],
"ahfs_class": null,
"substances": [
"CANAGLIFLOZIN",
"METFORMIN HYDROCHLORIDE"
],
"product_categorization": null
}See everything about metformin and canagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.